Stocks Down Under Videos

Get a 3-month FREE TRIAL to CONCIERGE now!

Concierge gives you timely BUY and SELL alerts on ASX-listed stocks

Test Concierge Now!

Island Pharmaceuticals (ASX:ILA) is in Phase 2 with ILA-101

October 31, 2024

ILA, Island Pharmaceuticals

Island Pharmaceuticals (ASX:ILA)

We spoke to Dr Paul MacLeman, Executive Chairman of Island Pharmaceuticals (ASX:ILA), about two significant drug development programmes.

ILA-101 is now in Phase 2 in dengue fever, an important area of unmet medical need globally. Meanwhile the company is doing its due diligence on Galidesivir, a broad-spectrum antiviral with demonstrated in vitro and in vivo activity against several RNA viruses where previous work has shown that it can be protective against both Ebola virus and Marburg virus. We believe the upside from each programme is immense.

Check out the in-depth research coverage of ILA by Pitt Street Research here!

 

Looking for the Best ASX Life Sciences Stocks to invest in right now?

 

 

View All